 |
3-chloro-4-fluorophenyl-[4-fluoro-4-[[(5-methylpyrimidin-2-ylmethyl)amino]methyl]piperidin-1yl]methanone |
|---|---|
| Trade Name | |
| Orphan Indication | Rett syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2013-10-25 00:00:00 |
| Sponsor | Neurolixis, Inc.;3210 Merryfield Row;San Diego, California, 92121 |
